Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will voluntarily withdraw its obeticholic acid product, Ocaliva, from the US market for the treatment of primary biliary cholangitis.
Intercept Pharmaceuticals will...